Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Medicus Pharma Ltd ( (MDCX) ).
Medicus Pharma will host a live fireside chat on March 19, 2026, led by Executive Chairman and CEO Dr. Raza Bokhari and moderated by Brookline Capital Markets analyst Kumar Raja, to discuss recent clinical progress. The company is positioning itself as an innovator in localized, minimally invasive oncology treatments, which could broaden its appeal to both clinical and strategic partners.
During the event, management will review positive topline Phase 2 results for SkinJect, a microneedle-mediated doxorubicin delivery system for nodular basal cell carcinoma, where the 200-µg arm achieved 73% clinical clearance versus 38% for the device-only control at Day 57. The data show clear separation between drug-loaded and control arms and are characterized by Medicus as decision-grade evidence supporting continued SkinJect development toward regulatory engagement and potential strategic partnerships, highlighting a non-surgical alternative that may help many patients avoid immediate surgical intervention.
The most recent analyst rating on (MDCX) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and heavy cash burn with negative equity) and bearish technicals (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend support, while recent financing provides some liquidity benefit but reinforces dilution/financing dependence.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd., listed on Nasdaq under the ticker MDCX, is a precision-guided biotech and life sciences company. It focuses on accelerating clinical development of novel and potentially disruptive therapeutic assets, with an emphasis on non-surgical treatment platforms such as its SkinJect microneedle-based drug delivery system for skin cancers like basal cell carcinoma.
Average Trading Volume: 3,768,004
Technical Sentiment Signal: Sell
Current Market Cap: $12.72M
For an in-depth examination of MDCX stock, go to TipRanks’ Overview page.